Poltreg S.a.

This study tests whether a combination of special immune cells (Tregs) and a drug (rituximab) can delay or prevent type 1 diabetes in children aged 6–16 who are at high risk but still produce insulin normally. About 150 participants will be randomly assigned to one of four groups…